NASDAQ:CDLXCardlytics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cardlytics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $75.26 +3.17 (+4.40 %) (As of 08/12/2020 02:11 PM ET) Add Compare Share Today's Range$73.74Now: $75.26▼$78.5950-Day Range$65.82MA: $71.34▼$79.1752-Week Range$27.33Now: $75.26▼$107.50Volume14,966 shsAverage Volume564,853 shsMarket Capitalization$2.05 billionP/E RatioN/ADividend YieldN/ABeta2.38 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cardlytics, Inc. operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. It also provides solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Read More Beat the Market (BTM) Rank™ 1.1 Analyst's Opinion Consensus RatingCardlytics has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $55.17, Cardlytics has a potential downside of 27.9% from its current price of $76.47.Amount of Analyst CoverageCardlytics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesCardlytics has received 188 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCardlytics has received 245 “underperform” votes. (Add your “underperform” vote.)Community SentimentCardlytics has received 56.58% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cardlytics and other stocks. Vote “Outperform” if you believe CDLX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CDLX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCardlytics does not currently pay a dividend.Dividend GrowthCardlytics does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cardlytics insiders have bought 115.00% more of their company's stock than they have sold. Specifically, they have bought $15,364,790.00 in company stock and sold $7,146,408.00 in company stock.Percentage Held by InsidersOnly 6.50% of the stock of Cardlytics is held by insiders.Percentage Held by Institutions83.37% of the stock of Cardlytics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cardlytics are expected to grow in the coming year, from ($2.14) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardlytics is -52.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardlytics is -52.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardlytics has a P/B Ratio of 16.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.58 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Computer programming, data processing, & other computer related Sub-IndustryN/A SectorBusiness Services Current SymbolNASDAQ:CDLX Previous Symbol CUSIPN/A CIK1666071 Webwww.cardlytics.com Phone888-798-5802Debt Debt-to-Equity RatioN/A Current Ratio3.45 Quick Ratio3.45Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$210.43 million Price / Sales9.76 Cash FlowN/A Price / Cash FlowN/A Book Value$4.78 per share Price / Book15.74Profitability EPS (Most Recent Fiscal Year)($0.75) Net Income$-17,140,000.00 Net Margins-18.86% Return on Equity-26.42% Return on Assets-17.67%Miscellaneous EmployeesN/A Outstanding Shares27,290,000Market Cap$2.05 billion Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $75.26 +3.17 (+4.40 %) (As of 08/12/2020 02:11 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CDLX News and Ratings via Email Sign-up to receive the latest news and ratings for CDLX and its competitors with MarketBeat's FREE daily newsletter. Cardlytics (NASDAQ:CDLX) Frequently Asked Questions How has Cardlytics' stock been impacted by COVID-19 (Coronavirus)? Cardlytics' stock was trading at $45.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CDLX shares have increased by 66.9% and is now trading at $76.47. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Cardlytics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cardlytics. When is Cardlytics' next earnings date? Cardlytics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Cardlytics. How were Cardlytics' earnings last quarter? Cardlytics Inc (NASDAQ:CDLX) released its earnings results on Tuesday, August, 4th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.36. The business had revenue of $28.22 million for the quarter, compared to analyst estimates of $30.84 million. Cardlytics had a negative return on equity of 26.42% and a negative net margin of 18.86%. The firm's revenue was down 42.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.12) earnings per share. View Cardlytics' earnings history. What price target have analysts set for CDLX? 6 equities research analysts have issued 12 month target prices for Cardlytics' stock. Their forecasts range from $26.00 to $75.00. On average, they anticipate Cardlytics' share price to reach $55.17 in the next year. This suggests that the stock has a possible downside of 27.9%. View analysts' price targets for Cardlytics. Has Cardlytics been receiving favorable news coverage? News stories about CDLX stock have been trending negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cardlytics earned a coverage optimism score of -2.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news about Cardlytics. Are investors shorting Cardlytics? Cardlytics saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 2,770,000 shares, a drop of 19.5% from the January 15th total of 3,440,000 shares. Based on an average daily trading volume, of 559,900 shares, the short-interest ratio is currently 4.9 days. View Cardlytics' Short Interest. Who are some of Cardlytics' key competitors? Some companies that are related to Cardlytics include Legend Biotech (DADA), HUYA (HUYA), DouYu International (DOYU), Medallia (MDLA), Switch (SWCH), Pluralsight (PS), SVMK (SVMK), Tripadvisor (TRIP), 21Vianet Group (VNET), Sabre (SABR), Internet Initiative Japan (IIJIY), Health Catalyst (HCAT), Model N (MODN), Eventbrite (EB) and the Rubicon Project (MGNI). View all competitors. What other stocks do shareholders of Cardlytics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Trade Desk (TTD), Caterpillar (CAT), Walt Disney (DIS), Docusign (DOCU), Advanced Micro Devices (AMD), Roku (ROKU), Square (SQ) and Twilio (TWLO). Who are Cardlytics' key executives? Cardlytics' management team includes the following people: Mr. Scott D. Grimes, Co-Founder, CEO & Director (Age 56)Ms. Lynne Marie Laube, Co-Founder, COO & Director (Age 49)Mr. David Evans, CFO & Head of Corp. Devel.Mr. Sathish Gaddipati, Chief Technology Officer (Age 52)Mr. Kirk L. Somers, Chief Legal & People Officer (Age 54) When did Cardlytics IPO? (CDLX) raised $76 million in an IPO on Friday, February 9th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers. What is Cardlytics' stock symbol? Cardlytics trades on the NASDAQ under the ticker symbol "CDLX." Who are Cardlytics' major shareholders? Cardlytics' stock is owned by a number of retail and institutional investors. Top institutional investors include Frontier Capital Management Co. LLC (1.67%), Jennison Associates LLC (1.63%), Victory Capital Management Inc. (1.16%), Great Lakes Advisors LLC (0.72%), Rockefeller Capital Management L.P. (0.61%) and Ziegler Capital Management LLC (0.34%). Company insiders that own Cardlytics stock include Aimia Inc, Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John L Jr Klinck, John V Balen, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes and Tony Weisman. View institutional ownership trends for Cardlytics. Which institutional investors are selling Cardlytics stock? CDLX stock was sold by a variety of institutional investors in the last quarter, including RMB Capital Management LLC, Frontier Capital Management Co. LLC, Hancock Whitney Corp, Hussman Strategic Advisors Inc., Jennison Associates LLC, and Brave Asset Management Inc.. Company insiders that have sold Cardlytics company stock in the last year include Aimia Inc, Andrew Christiansen, Bryce Youngren, David Leslie Adams, David Thomas Evans, John L Jr Klinck, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Scott D Grimes, and Tony Weisman. View insider buying and selling activity for Cardlytics. Which institutional investors are buying Cardlytics stock? CDLX stock was bought by a variety of institutional investors in the last quarter, including Great Lakes Advisors LLC, First Trust Advisors LP, Serengeti Asset Management LP, Tygh Capital Management Inc., California Public Employees Retirement System, Ziegler Capital Management LLC, Roubaix Capital LLC, and Victory Capital Management Inc.. Company insiders that have bought Cardlytics stock in the last two years include Clifford Sosin, and John V Balen. View insider buying and selling activity for Cardlytics. How do I buy shares of Cardlytics? Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cardlytics' stock price today? One share of CDLX stock can currently be purchased for approximately $76.47. How big of a company is Cardlytics? Cardlytics has a market capitalization of $2.09 billion and generates $210.43 million in revenue each year. The company earns $-17,140,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. What is Cardlytics' official website? The official website for Cardlytics is www.cardlytics.com. How can I contact Cardlytics? Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected] This page was last updated on 8/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
